Denali Therapeutics (NASDAQ: DNLI) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Denali Therapeutics to related businesses based on the strength of its earnings, dividends, institutional ownership, profitability, risk, valuation and analyst recommendations.
This is a summary of recent recommendations and price targets for Denali Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Denali Therapeutics Competitors||954||3405||11909||239||2.69|
Valuation and Earnings
This table compares Denali Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Denali Therapeutics Competitors||$290.27 million||$35.99 million||54.38|
Denali Therapeutics’ competitors have higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Denali Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Denali Therapeutics Competitors||-5,322.24%||-84.37%||-35.66%|
Denali Therapeutics beats its competitors on 6 of the 11 factors compared.
Denali Therapeutics Company Profile
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.